Abstract 3685
Background
The NETTER-1 trial has recently shown the efficacy of 177Lu-DOTATATE in association with Octreotide (OCT) in somatostatin receptor positive midgut NETs, progressing to OCT. The aim of this analysis was to evaluate the role of SSA in association to PRRT beyond PD or after switch to other SSA at PD.
Methods
Out of 107 WD EP-NETs, treated with PRRT (90Y-DOTATOC/DOTATATE and/or 177Lu-DOTATOC/DOTATATE) at the Istituto Nazionale Tumori of Milan, from 2008 to 2017, 69 patients (pts) treated with the combination of PRRT and SSA (OCT or Lanreotide, LAN) after SSA treatment failure, were evaluated for present analysis. We identified 2 groups: S1, pts who kept the same SSA treatment beyond first PD; S2, pts who switched the SSA with another SSA after first PD. Median Progression Free Survival (mPFS) (from the start of first SSA) and Overall Survival (OS) have been evaluated using the Kaplan-Maier method.
Results
In S1 (n = 47) and S2 (n = 22) groups median age and sex were 58 ys (range 29-78) and 59.5% males vs 52.5 ys (range 35-78) and 45.4% males, respectively. We had a P-NETs percentage of 34% vs 40.9% in the S1 vs S2 groups, respectively. The most of pts (82.9% in S1 and 86.3% in S2) received PRRT with alternate radionuclides (90Y/177Lu). Overall the median number of PRRT cycles was 4.2 in S1 and 4.8 in S2 (p = 0.09). In the S1 (SSA beyond PD) group PRRT was associated with OCT in 74.5% and LAN in 25.5% of pts. In the S2 group (SSA switched with other SSA) PRRT was associated with OCT in 27.3% and LAN in 72.7% of pts. In the overall population the mPFS and OS were 70 (CI95% 52.8-87.1) and 82 (CI95% 66.7-97.2) months (mo), respectively. The difference on mPFS was 53 and 127 mo in S1 and S2, respectively (p = 0.001; HR: 0.31; CI95% 0.15-0.63). In S1 group the OS was 69 mo vs 150 mo in S2 (p = 0.004; HR: 0.32; CI95% 0.14-0.71).
Conclusions
Despite the retrospective nature of the analysis and the low number of pts, we found a significant difference on mPFS and OS between S1 and S2 groups. In pts with advanced WD EP-NETs treated with PRRT plus SSA after SSA failure, the “switch” strategy of SSA after PD, might improve PFS and/or OS.
Clinical trial identification
Legal entity responsible for the study
Sara Pusceddu.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
N. Prinzi: Italfarmaco, Novartis: Consultancies. G. Lo Russo: AstraZeneca, BMS, MSD: Consultancies. S. Pusceddu: Novartis, Ipsen, Italfarmaco, Pfizer and advanced accelerator applications (AAA). All other authors have declared no conflicts of interest.
Resources from the same session
1159 - Molecular characterization and search for founding effects in Canarian families with Hereditary Breast and Ovarian Cancer Syndrome
Presenter: Elisenda Llabres Valenti
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3725 - Effect of the polymorphism rs2066844 of the NOD2 gene on colon cancer incidence in a high cardiovascular risk population. Modulation by gender
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3708 - Effect of the polymorphisms rs1476413, rs1801131, rs4846052 and rs6541003 of the MTHFR gene on prostate cancer in a high cardiovascular risk population
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5057 - Association of a genetic variant in cyclin-dependent kinase Inhibitor 2A gene with the increased risk of breast cancer
Presenter: Soodabeh Shahid Sales
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5970 - Investigating the role of HAT protein TIP60 in regulating functional dynamics of nuclear receptor PXR
Presenter: KARISHMA BAKSHI
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1360 - The role of downregulated SIRT3 expression in patients with hepatocellular carcinoma
Presenter: Hanhee Jo
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1634 - Prediction and Intervention of Colorectal Cancer Risk with Artificial Intelligent System
Presenter: Yang Ge
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4921 - Measuring the Efficiency of Cancer Care in Europe
Presenter: Rikard Althin
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer patients
Presenter: Chih-Yung Yang
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.
Presenter: Natalia Levitskaya
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract